Merck Partners with Medisafe to Help Improve Medication Adherence for Cardiometabolic Patients

MerckMerck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication intake and adhere to prescribed treatment regimens. In the countries of scope Merck patients will have access to a customized version of Medisafe's mobile platform that could combine reminders, motivation and support systems, targeted content, coupons and interventions in their local language.

"This is an extremely important step towards realizing our vision of supporting patients with comprehensive, integrated, value-added services that look beyond medicines to improve treatment outcomes. We are confident that offering such a solution to our patients has the potential to significantly improve medication adherence by giving patients and carers the tools to organize, understand and manage their medications," said Simon Sturge, Chief Operating Officer at Merck's Biopharma business.

Medisafe is a leading medication management and adherence solution co-owned by M Ventures, which has been named top app for medication management by November 2017 IQVIA (Quintiles IMS) report. It has received endorsements from the American Pharmacy Association, Journal of Medical Internet Research (JMIR), and Ranked Health. Medisafe has already delivered high rates of adherence across multiple disease areas, and recorded significant improvements - notably, 86% of Stage 2 hypertensive users reduced their risk category to Stage 1 or below.(1)

This digital solution will complement Merck’s current offering of Primary Care medicines for cardiometabolic conditions, which includes treatments for type 2 diabetes, thyroid disorders, and cardiovascular diseases. Although many medications are effective in combating chronic diseases, their full benefits are often not realized by the patients. Approximately 50% of patients do not adhere to long-term therapies,(2,3) and this percentage is much higher in developing countries.(3) A systematic review of anti-diabetic therapies found wide-ranging adherence rates between 36% to 93%.(4) This is of great concern when adherence to medication is critical to positive outcomes.

Factors contributing to poor medication adherence are myriad and include those that are related to patients, physicians and healthcare systems, so improving adherence requires a continuous and dynamic process.(3) Because of this complex matrix of factors, our knowledge of the underlying causes of poor medication adherence is still very limited. The collaboration with Medisafe offers the possibility to reveal new overall insights into patients’ behaviour, through data collected by Medisafe, which may contribute to improved chronic disease management in the future.

Brazil, Russia and Mexico are the first three countries where patients receiving Merck's primary care medicines will have access to a customized version of Medisafe. Globally, around 60 million patients with chronic conditions are estimated to be treated with Merck’s medications daily.

About Medisafe

Medisafe is a leading medication management and adherence solution co-owned by M Ventures. It has more than 4 million registered users, 4 billion patient data points and 140,000 apple store reviews with a 4.5-5 rating. It has received endorsements from the American Pharmacy Association, Journal of Medical Internet Research (JMIR), and Ranked Health. In addition, Medisafe is HIPPA (Health Insurance Portability and Accountability Act) compliant with the latest ISO 27001 security protection for patient data. In a recent study, its usage resulted in a 20% rise in prescription refills versus control (IMS Study).5 It is, therefore, not surprising that Medisafe has been named top app for medication management by November 2017 IQVIA (Quintiles IMS) report.

About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2017, Merck generated sales of € 15.3 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

1. Medisafe website. Available at: https://medisafe.com/research/ Accessed January 2018
2. Brown MT, Bussell JK. Medication Adherence: WHO Cares? Mayo Clin Proc. 2011 Apr; 86:304-314.
3. World Health Organization. Adherence to Long-Term Therapies. Evidence for Action Geneva: World Health Organization; 2003. Available at: http://whqlibdoc.who.int/publications/2003/9241545992.pdf Accessed January 2017.
4. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004; 27:1218-1224.
5. Medisafe website. Available at: https://medisafe.com/research/case-study-medisafe-platform-app-increase-medication-adherence/ Accessed January 2018.

Most Popular Now

Is Your Marketing Effective for an NHS C…

How can you make sure you get the right message across to an NHS chief information officer, or chief nursing information officer? Replay this webinar with Professor Natasha Phillips, former...

Welcome Evo, Generative AI for the Genom…

Brian Hie runs the Laboratory of Evolutionary Design at Stanford, where he works at the crossroads of artificial intelligence and biology. Not long ago, Hie pondered a provocative question: If...

We could Soon Use AI to Detect Brain Tum…

A new paper in Biology Methods and Protocols, published by Oxford University Press, shows that scientists can train artificial intelligence (AI) models to distinguish brain tumors from healthy tissue. AI...

Telehealth Significantly Boosts Treatmen…

New research reveals a dramatic improvement in diagnosing and curing people living with hepatitis C in rural communities using both telemedicine and support from peers with lived experience in drug...

AI can Predict Study Results Better than…

Large language models, a type of AI that analyses text, can predict the results of proposed neuroscience studies more accurately than human experts, finds a new study led by UCL...

Research Study Shows the Cost-Effectiven…

Earlier research showed that primary care clinicians using AI-ECG tools identified more unknown cases of a weak heart pump, also called low ejection fraction, than without AI. New study findings...

Using AI to Treat Infections more Accura…

New research from the Centres for Antimicrobial Optimisation Network (CAMO-Net) at the University of Liverpool has shown that using artificial intelligence (AI) can improve how we treat urinary tract infections...

New Guidance for Ensuring AI Safety in C…

As artificial intelligence (AI) becomes more prevalent in health care, organizations and clinicians must take steps to ensure its safe implementation and use in real-world clinical settings, according to an...

Remote Telemedicine Tool Found Highly Ac…

Collecting images of suspicious-looking skin growths and sending them off-site for specialists to analyze is as accurate in identifying skin cancers as having a dermatologist examine them in person, a...

Philips Aims to Advance Cardiac MRI Tech…

Royal Philips (NYSE: PHG, AEX: PHIA) and Mayo Clinic announced a research collaboration aimed at advancing MRI for cardiac applications. Through this investigation, Philips and Mayo Clinic will look to...

New Study Reveals Why Organisations are …

The slow adoption of blockchain technology is partly driven by overhyped promises that often obscure the complex technological, organisational, and environmental challenges, according to research from the University of Surrey...

Deep Learning Model Accurately Diagnoses…

Using just one inhalation lung CT scan, a deep learning model can accurately diagnose and stage chronic obstructive pulmonary disease (COPD), according to a study published today in Radiology: Cardiothoracic...